Literature DB >> 33638633

Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations from the Cancer Neuroscience Initiative Working Group.

Ashley M Henneghan1, Kathleen Van Dyk2, Tara Kaufmann3, Rebecca Harrison4, Christopher Gibbons5, Cobi Heijnen6, Shelli R Kesler7.   

Abstract

Cancer and its treatments are associated with increased risk for cancer-related cognitive impairment (CRCI). Methods and measures used to study and assess self-reported CRCI (sr-CRCI), however, remain diverse, resulting in heterogeneity across studies. The Patient-Reported Outcomes Working Group has been formed to promote homogeneity in the methods used to study sr-CRCI. In this report, using a psychometric taxonomy, we inventory and appraise instruments used in research to measure sr-CRCI, and we consider advances in patient-reported outcome methodology. Given its psychometric properties, we recommend the Patient-Reported Outcome Measurement Information System Cognitive Function Short Form 8a for measurement of sr-CRCI in cancer patients and survivors, at a minimum, in order to increase scientific rigor and progress in addressing CRCI.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cancer related cognitive dysfunction; measurement; patient reported outcomes; recommendations

Year:  2021        PMID: 33638633      PMCID: PMC8849125          DOI: 10.1093/jnci/djab027

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  95 in total

1.  Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function-Adult version in healthy adults and application to attention-deficit/hyperactivity disorder.

Authors:  Robert M Roth; Charles E Lance; Peter K Isquith; Adina S Fischer; Peter R Giancola
Journal:  Arch Clin Neuropsychol       Date:  2013-05-14       Impact factor: 2.813

2.  Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

Authors:  Vincent Koppelmans; Michiel B de Ruiter; Fedde van der Lijn; Willem Boogerd; Caroline Seynaeve; Aad van der Lugt; Henri Vrooman; Wiro J Niessen; Monique M B Breteler; Sanne B Schagen
Journal:  Breast Cancer Res Treat       Date:  2011-12-29       Impact factor: 4.872

3.  Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients.

Authors:  Sanne B Schagen; Enny Das; Ivar Vermeulen
Journal:  Psychooncology       Date:  2011-07-18       Impact factor: 3.894

4.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Authors:  Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans
Journal:  Lancet Neurol       Date:  2009-08-07       Impact factor: 44.182

5.  Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls.

Authors:  Shelli R Kesler; Jeffrey S Wefel; S M Hadi Hosseini; Maria Cheung; Christa L Watson; Fumiko Hoeft
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

6.  Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.

Authors:  Michiel B de Ruiter; Liesbeth Reneman; Willem Boogerd; Dick J Veltman; Frits S A M van Dam; Aart J Nederveen; Epie Boven; Sanne B Schagen
Journal:  Hum Brain Mapp       Date:  2010-07-28       Impact factor: 5.038

7.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

8.  Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.

Authors:  Janette L Vardy; Haryana M Dhillon; Gregory R Pond; Sean B Rourke; Tsegaye Bekele; Corrinne Renton; Anna Dodd; Haibo Zhang; Philip Beale; Stephen Clarke; Ian F Tannock
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

Review 9.  Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Authors:  Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

10.  Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial.

Authors:  Kajal Gokal; Fehmidah Munir; Samreen Ahmed; Kiran Kancherla; Deborah Wallis
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

View more
  5 in total

1.  A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.

Authors:  Sheila N Garland; Josée Savard; Sarah L Eisel; Richard J Wassersug; Nicholas J Rockwood; John Thoms; Heather S L Jim; Brian D Gonzalez
Journal:  Cancer       Date:  2021-08-19       Impact factor: 6.860

2.  Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life.

Authors:  Kathleen Van Dyk; Lucy Wall; Brandon F Heimberg; Justin Choi; Catalina Raymond; Chencai Wang; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson; Phioanh Nghiemphu
Journal:  CNS Oncol       Date:  2022-05-18

Review 3.  Self-Reported Cognitive Function in Persons with Nonneurological Chronic Diseases: A Systematic Review.

Authors:  Heather Cuevas; Valerie Danesh; Ashley Henneghan
Journal:  J Aging Res       Date:  2022-03-31

4.  Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment.

Authors:  Ning Yi Yap; Yi Long Toh; Chia Jie Tan; Munjal M Acharya; Alexandre Chan
Journal:  Cytokine       Date:  2021-05-10       Impact factor: 3.861

5.  Screening for cognitive symptoms among cancer patients during chemotherapy: Sensitivity and specificity of a single item self-report cognitive change score.

Authors:  Joanna E Fardell; Victoria Bray; Melanie L Bell; Brooke Rabe; Haryana Dhillon; Janette L Vardy
Journal:  Psychooncology       Date:  2022-03-30       Impact factor: 3.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.